Profiling targetable immune checkpoints in osteosarcoma
Osteosarcomas are aggressive bone tumors for which therapeutic advances have not improved over several decades. Unlike most pediatric tumors, the osteosarcoma genome is remarkably unstable, characterized by numerous copy number alterations and chromosomal structural aberrations. In this study, we as...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1475873 |
id |
doaj-1f073da43f784f93bc787603d402b053 |
---|---|
record_format |
Article |
spelling |
doaj-1f073da43f784f93bc787603d402b0532020-11-25T03:02:11ZengTaylor & Francis GroupOncoImmunology2162-402X2018-12-0171210.1080/2162402X.2018.14758731475873Profiling targetable immune checkpoints in osteosarcomaTroy A McEachron0Timothy J Triche1Laurie Sorenson2David M Parham3John D Carpten4Department of Translational GenomicsNorris Comprehensive Cancer CenterDepartment of Translational GenomicsChildren’s Hospital Los AngelesDepartment of Translational GenomicsOsteosarcomas are aggressive bone tumors for which therapeutic advances have not improved over several decades. Unlike most pediatric tumors, the osteosarcoma genome is remarkably unstable, characterized by numerous copy number alterations and chromosomal structural aberrations. In this study, we asked if the targetable immune checkpoints CD274 (PD-L1), PDCD1LG2 (PD-L2), CD276 (B7-H3) and IDO1 are impacted by copy number alterations in osteosarcoma. Of the 215 osteosarcoma samples investigated, PD-L1/PD-L2, B7-H3 and IDO1 were independently gained at frequencies of approximately 8–9%, with a cumulative frequency of approximately 24%. RNA sequencing data from two independent cohorts revealed that B7-H3 is the most highly expressed immune checkpoint gene among the four investigated. We also show that IDO1 is preferentially expressed in pediatric solid tumors and that increased protein expression of B7-H3 and IDO1 are significantly associated with inferior survival in patient samples. Using human osteosarcoma cell lines, we demonstrate that IDO1 is gained in MG63 and G292 cells and that the IDO1 inhibitor, epacadostat, inhibits the enzymatic activity of IDO1 in a dose-dependent manner in these cells. Together, these data reveal the genomic and transcriptomic profiles of PD-L1, PD-L2, B7-H3 and IDO1 in osteosarcoma and identifies a potential context for targeted immunotherapeutic intervention in a subset of patients.http://dx.doi.org/10.1080/2162402X.2018.1475873osteosarcomapd-l1pd-l2b7-h3cd276ido1checkpoint |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Troy A McEachron Timothy J Triche Laurie Sorenson David M Parham John D Carpten |
spellingShingle |
Troy A McEachron Timothy J Triche Laurie Sorenson David M Parham John D Carpten Profiling targetable immune checkpoints in osteosarcoma OncoImmunology osteosarcoma pd-l1 pd-l2 b7-h3 cd276 ido1 checkpoint |
author_facet |
Troy A McEachron Timothy J Triche Laurie Sorenson David M Parham John D Carpten |
author_sort |
Troy A McEachron |
title |
Profiling targetable immune checkpoints in osteosarcoma |
title_short |
Profiling targetable immune checkpoints in osteosarcoma |
title_full |
Profiling targetable immune checkpoints in osteosarcoma |
title_fullStr |
Profiling targetable immune checkpoints in osteosarcoma |
title_full_unstemmed |
Profiling targetable immune checkpoints in osteosarcoma |
title_sort |
profiling targetable immune checkpoints in osteosarcoma |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2018-12-01 |
description |
Osteosarcomas are aggressive bone tumors for which therapeutic advances have not improved over several decades. Unlike most pediatric tumors, the osteosarcoma genome is remarkably unstable, characterized by numerous copy number alterations and chromosomal structural aberrations. In this study, we asked if the targetable immune checkpoints CD274 (PD-L1), PDCD1LG2 (PD-L2), CD276 (B7-H3) and IDO1 are impacted by copy number alterations in osteosarcoma. Of the 215 osteosarcoma samples investigated, PD-L1/PD-L2, B7-H3 and IDO1 were independently gained at frequencies of approximately 8–9%, with a cumulative frequency of approximately 24%. RNA sequencing data from two independent cohorts revealed that B7-H3 is the most highly expressed immune checkpoint gene among the four investigated. We also show that IDO1 is preferentially expressed in pediatric solid tumors and that increased protein expression of B7-H3 and IDO1 are significantly associated with inferior survival in patient samples. Using human osteosarcoma cell lines, we demonstrate that IDO1 is gained in MG63 and G292 cells and that the IDO1 inhibitor, epacadostat, inhibits the enzymatic activity of IDO1 in a dose-dependent manner in these cells. Together, these data reveal the genomic and transcriptomic profiles of PD-L1, PD-L2, B7-H3 and IDO1 in osteosarcoma and identifies a potential context for targeted immunotherapeutic intervention in a subset of patients. |
topic |
osteosarcoma pd-l1 pd-l2 b7-h3 cd276 ido1 checkpoint |
url |
http://dx.doi.org/10.1080/2162402X.2018.1475873 |
work_keys_str_mv |
AT troyamceachron profilingtargetableimmunecheckpointsinosteosarcoma AT timothyjtriche profilingtargetableimmunecheckpointsinosteosarcoma AT lauriesorenson profilingtargetableimmunecheckpointsinosteosarcoma AT davidmparham profilingtargetableimmunecheckpointsinosteosarcoma AT johndcarpten profilingtargetableimmunecheckpointsinosteosarcoma |
_version_ |
1724690940388442112 |